C-Path Institute’s New Washington Office May Enhance PGx Efforts, Funding Opportunities | GenomeWeb
The Critical Path Institute’s new presence in Washington, DC, may help fuel its pharmacogenomics research, particularly drug-diagnostic co-development partnerships.
 
Earlier this month, the Tucson, Ariz.-based non-profit opened an office in the nation’s capital, which placed it in the midst of Congress, regulatory agencies, research organizations, and biotechnology companies. The new digs will likely help raise the profile of C-Path initiatives, including the institute’s PGx efforts.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.